Literature DB >> 17108032

Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells.

Ping Liu1, Mohammad Jamaluddin, Kui Li, Roberto P Garofalo, Antonella Casola, Allan R Brasier.   

Abstract

Respiratory syncytial virus (RSV) is one of the most common viral pathogens causing severe lower respiratory tract infections in infants and young children. Infected host cells detect and respond to RNA viruses using different mechanisms in a cell-type-specific manner, including retinoic acid-inducible gene I (RIG-I)-dependent and Toll-like receptor (TLR)-dependent pathways. Because the relative contributions of these two pathways in the recognition of RSV infection are unknown, we examined their roles in this study. We found that RIG-I helicase binds RSV transcripts within 12 h of infection. Short interfering RNA (siRNA)-mediated RIG-I "knockdown" significantly inhibited early nuclear factor-kappaB (NF-kappaB) and interferon response factor 3 (IRF3) activation 9 h postinfection (p.i.). Consistent with this finding, RSV-induced beta interferon (IFN-beta), interferon-inducible protein 10 (IP-10), chemokine ligand 5 (CCL-5), and IFN-stimulated gene 15 (ISG15) expression levels were decreased in RIG-I-silenced cells during the early phase of infection but not at later times (18 h p.i.). In contrast, siRNA-mediated TLR3 knockdown did not affect RSV-induced NF-kappaB binding but did inhibit IFN-beta, IP-10, CCL-5, and ISG15 expression at late times of infection. Further studies revealed that TLR3 knockdown significantly reduced NF-kappaB/RelA transcription by its ability to block the activating phosphorylation of NF-kappaB/RelA at serine residue 276. We further found that TLR3 induction following RSV infection was regulated by RIG-I-dependent IFN-beta secreted from infected airway epithelial cells and was mediated by both IFN response-stimulated element (ISRE) and signal transducer and activator of transcription (STAT) sites in its proximal promoter. Together these findings indicate distinct temporal roles of RIG-I and TLR3 in mediating RSV-induced innate immune responses, which are coupled to distinct pathways controlling NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108032      PMCID: PMC1797494          DOI: 10.1128/JVI.01740-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Respiratory syncytial virus and parainfluenza virus.

Authors:  C B Hall
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

2.  Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.

Authors:  J M Emeny; M J Morgan
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

3.  VISA is an adapter protein required for virus-triggered IFN-beta signaling.

Authors:  Liang-Guo Xu; Yan-Yi Wang; Ke-Jun Han; Lian-Yun Li; Zhonghe Zhai; Hong-Bing Shu
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

4.  IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression.

Authors:  Jorma Tissari; Jukka Sirén; Seppo Meri; Ilkka Julkunen; Sampsa Matikainen
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

5.  Hitching RIG to action.

Authors:  Ganes C Sen; Saumendra N Sarkar
Journal:  Nat Immunol       Date:  2005-11       Impact factor: 25.606

6.  Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1).

Authors:  Linda Vermeulen; Gert De Wilde; Petra Van Damme; Wim Vanden Berghe; Guy Haegeman
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

7.  Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection.

Authors:  Brian D Rudd; Jetse J Smit; Richard A Flavell; Lena Alexopoulou; Matthew A Schaller; Achim Gruber; Aaron A Berlin; Nicholas W Lukacs
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

8.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

9.  Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains.

Authors:  Masako Tanabe; Mitsue Kurita-Taniguchi; Kaoru Takeuchi; Makoto Takeda; Minoru Ayata; Hisashi Ogura; Misako Matsumoto; Tsukasa Seya
Journal:  Biochem Biophys Res Commun       Date:  2003-11-07       Impact factor: 3.575

Review 10.  Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response.

Authors:  James Harris; Dirk Werling
Journal:  Cell Microbiol       Date:  2003-10       Impact factor: 3.715

View more
  160 in total

1.  Human metapneumovirus glycoprotein G inhibits TLR4-dependent signaling in monocyte-derived dendritic cells.

Authors:  Deepthi Kolli; Xiaoyong Bao; Tianshuang Liu; Chao Hong; Tian Wang; Roberto P Garofalo; Antonella Casola
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virus-infected immunocompromised mice.

Authors:  Na Zang; Xiaohong Xie; Yu Deng; Shengde Wu; Lijia Wang; Caijing Peng; Simin Li; Ke Ni; Yan Luo; Enmei Liu
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 3.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

Review 4.  Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity.

Authors:  A G Bowie
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Nuclear factor κB2 p52 protein has a role in antiviral immunity through IκB kinase epsilon-dependent induction of Sp1 protein and interleukin 15.

Authors:  Sarah L Doyle; Kari Ann Shirey; Anne F McGettrick; Elaine F Kenny; Susan Carpenter; Brian E Caffrey; Siobhan Gargan; Susan R Quinn; Jorge H Caamaño; Paul Moynagh; Stefanie N Vogel; Luke A O'Neill
Journal:  J Biol Chem       Date:  2013-07-19       Impact factor: 5.157

6.  Impaired virus replication and decreased innate immune responses to viral infections in nasal epithelial cells from patients with allergic rhinitis.

Authors:  A Głobińska; M Pawełczyk; A Piechota-Polańczyk; A Olszewska-Ziąber; S Moskwa; A Mikołajczyk; A Jabłońska; P K Zakrzewski; M Brauncajs; M Jarzębska; S Taka; N G Papadopoulos; M L Kowalski
Journal:  Clin Exp Immunol       Date:  2016-11-14       Impact factor: 4.330

Review 7.  Inflammasomes and its importance in viral infections.

Authors:  Gaurav Shrivastava; Moisés León-Juárez; Julio García-Cordero; David Eduardo Meza-Sánchez; Leticia Cedillo-Barrón
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

8.  Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state.

Authors:  Sif Hansdottir; Martha M Monick; Nina Lovan; Linda Powers; Alicia Gerke; Gary W Hunninghake
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

9.  Sustained activation of interferon regulatory factor 3 during infection by paramyxoviruses requires MDA5.

Authors:  Nathalie Grandvaux; Xiaochun Guan; Fabrice Yoboua; Nicolas Zucchini; Karin Fink; Priscilla Doyon; Lydie Martin; Marc J Servant; Stéfany Chartier
Journal:  J Innate Immun       Date:  2014-04-30       Impact factor: 7.349

10.  Opposing roles of RNA receptors TLR3 and RIG-I in the inflammatory response to double-stranded RNA in a Kaposi's sarcoma cell line.

Authors:  April J Livengood; Christina C N Wu; Dennis A Carson
Journal:  Cell Immunol       Date:  2007-12-26       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.